Mental Disorders: Clinical Trials

524 trials for Mental Disorders, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

278 completed, 66 unknown, 62 recruiting, 38 terminated. 524 Early Phase 1.

By phase and status

PhaseTrialsStatus
Early Phase 1524Completed 278, Unknown 66, Recruiting 62, Terminated 38, Not yet recruiting 35, Withdrawn 22, Active not recruiting 19, Enrolling by invitation 3, Suspended 1

Follow Mental Disorders: new trials by email Literature Review of Mental Disorders trials Research Report on Mental Disorders

Trials (filtered) newest first · largest first

All 524 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Understanding Non-invasive Vagus Nerve Stimulation Effects in PTSD
transcutaneous auricular vagus nerve stimulation, sham transcutaneous auricular vagus nerve stimulation - PTSD - Post Traumatic Stress Disorder
Early Phase 1Not yet recruitingWayne State University602027-04-012026-07-13
PTSD and Alcohol Couples Treatment for Veterans
COPE + BFIT - PTSD, AUD
Early Phase 1Not yet recruitingVA Office of Research and Development802027-03-012026-02-10
Research Investigating Drug Effects-2 (RiDE-2)
Placebo Oral Capsule, THC - Cannabis Use, Substance Use Disorder (SUD)
Early Phase 1Not yet recruitingUniversity of Illinois at Chicago1442027-01-042026-10-22
Evaluating the Delivery and Effects of THC Vaping Liquids in the Bloodstream
Biospecimen Collection, Cannabis sativa Extract, Nicotine - Cannabis Dependence
Early Phase 1Not yet recruitingRoswell Park Cancer Institute602026-12-152026-11-16
Addressing Violence in the Context of Opioid Use Disorder Care
SHE-OUD - Sexual Violence, Opioid Use Disorder
Early Phase 1Not yet recruitingLifespan202026-12-052026-11-17
Examining the Role of Sensitivity to Uncertain Threat and Alcohol Response in Risk for Alcohol Use Disorder Following Sexual Assault in College Women
Alcohol, Placebo - Sexual Assault, Alcohol Intoxication
Early Phase 1Not yet recruitingOhio State University2202026-12-012026-10-26
Cholinergic Enhancement of Theta
COBENFY KarXT (50/20 mg), Control - Epilepsy, Seizures
Early Phase 1Not yet recruitingUniversity of Texas Southwestern Medical Center502026-12-012026-09-29
Reducing Days DELirious With DEXmedetomidine as Part of an Intensive Care Unit Sleep Promotion Bundle
Dexmedetomidine, Control (placebo) group - Sleep, Delirium
Early Phase 1Not yet recruitingUniversity of Alberta502026-12-012026-10-13
Kava Aging and Mobility Study
AB-free kava, Placebo - Old Adults, Sleep Quality
Early Phase 1Not yet recruitingUniversity of Florida402026-12-012026-08-31
Lung Health and Breath Biomarkers: Acute Effects of Inhaled Cannabis
Cannabis (THC), Tobacco Cigarette - Cannabis Use, Tobacco
Early Phase 1Not yet recruitingHannah Harris122026-12-012026-11-04
reALIGNing Circadian Rhythm and Promoting Sleep in the Intensive Care Unit
Sleep chronobundle, Control - Sleep, Circadian Dysregulation
Early Phase 1Not yet recruitingUniversity of Alberta502026-11-302026-10-21
Guanfacine and Cromolyn Sodium for POTS: The DBPOTS Trial
Guanfacine (GFC), Cromolyn Sodium, Placebo - Postural Orthostatic Tachycardia Syndrome (POTS), Dysautonomia
Early Phase 1Not yet recruitingJohns Hopkins University252026-11-202026-11-12
Pain Sensitivity, Alcohol-Induced Analgesia, and Heavy Drinking in Individuals With Opioid Use Disorder
Alcohol, Placebo - Opioid Use Disorder, Alcohol Intoxication
Early Phase 1Not yet recruitingOhio State University902026-11-012026-10-26
Predictors & Mechanisms of Adolescent PTSD
Repeated imaginal exposure: Script Driven Imagery (SDI) task - Posttraumatic Stress Disorder (PTSD), Trauma Exposure
Early Phase 1Not yet recruitingMedical University of South Carolina1802026-11-012026-10-09
Haloperidol For Outpatient Symptom Management in Patients Diagnosed With Cannabinoid Hyperemesis Syndrome in the Emergrency Department
Haloperidol - Cannabinoid Hyperemesis Syndrome
Early Phase 1Not yet recruitingUniversity of Illinois at Chicago1002026-11-012026-09-01
Aprepitant for the Treatment of CLIFAHDD
Aprepitant Powder for Oral Suspension - CLIFAHDD, Congenital Contractures of the Limbs and Face, Hypotonia, and Developmental Delay
Early Phase 1RecruitingThe University of Texas Health Science Center at San Antonio52026-10-312026-11-05
A Web-based Intervention Program for Postpartum Depression
Web-based program for postpartum depression - Postpartum Depression (PPD), Web-based Intervention
Early Phase 1RecruitingBabes-Bolyai University302026-10-272026-10-28
Safety, Tolerability, and Pharmacokinetics of MCAM in Healthy Adult Participants
Placebo, MCAM - Opioid Use Disorder
Early Phase 1Not yet recruitingThe University of Texas Health Science Center at San Antonio242026-10-222026-10-05
Individualized (fMRI-guided) TMS Intervention for Post-Traumatic Stress Disorder (PTSD)
Active Transcranial Magnetic Stimulation (TMS), Sham Transcranial Magnetic Stimulation (TMS) - PTSD, Post Traumatic Stress Disorder (PTSD)
Early Phase 1Not yet recruitingUniversity of Pennsylvania602026-10-122026-08-31
Digital Intervention Delivered Via Street Medicine to Increase HIV and Substance Use Care Among Survivors of Sex Trafficking
CONNECT - Sex Trafficking, HIV
Early Phase 1Not yet recruitingLifespan602026-10-052026-07-13

Showing 20 of 524. Sign in to see all of them.

Narrower conditions

Alzheimer Disease (63)  ·  Anxiety Disorders (41)  ·  Stress Disorders, Post-Traumatic (40)  ·  Depression (37)  ·  Cognitive Dysfunction (34)  ·  Opioid-Related Disorders (33)  ·  Alcoholism (30)  ·  Marijuana Abuse (29)  ·  Depressive Disorder, Major (28)  ·  Schizophrenia (27)  ·  Tobacco Use Disorder (27)  ·  Substance-Related Disorders (24)  ·  Psychotic Disorders (21)  ·  Attention Deficit Disorder with Hyperactivity (18)  ·  Sleep Initiation and Maintenance Disorders (18)

Broader conditions

Nervous System Diseases (159)  ·  Chemically-Induced Disorders (151)  ·  Neurocognitive Disorders (130)  ·  Substance-Related Disorders (127)  ·  Pathological Conditions, Signs and Symptoms (102)  ·  Central Nervous System Diseases (99)  ·  Behavior (97)  ·  Brain Diseases (96)  ·  Signs and Symptoms (91)  ·  Neurodegenerative Diseases (79)  ·  Neurologic Manifestations (74)  ·  Dementia (72)  ·  Tauopathies (61)  ·  Behavioral Symptoms (49)

Interventions

Dronabinol (21)  ·  Ketamine (19)  ·  Nicotine (14)  ·  Acetylcysteine (11)  ·  Dexmedetomidine (10)  ·  nabiximols (10)  ·  Cannabidiol (9)  ·  Ethanol (9)  ·  Oxytocin (9)  ·  Methylphenidate (8)  ·  Cycloserine (7)  ·  Psilocybin (7)  ·  Sodium Chloride (7)  ·  Cognitive Behavioral Therapy (6)  ·  Deep Brain Stimulation (6)

Sponsors

Yale University (37)  ·  Medical University of South Carolina (11)  ·  University of California, San Francisco (11)  ·  University of California, San Diego (9)  ·  Johns Hopkins University (7)  ·  Massachusetts General Hospital (7)  ·  Mclean Hospital (7)  ·  The University of Texas Health Science Center at San Antonio (7)  ·  University of Pennsylvania (7)  ·  Beijing Pins Medical Co., Ltd (5)  ·  National Institute on Alcohol Abuse and Alcoholism (NIAAA) (5)  ·  University of California, Los Angeles (5)  ·  University of Minnesota (5)  ·  VA Office of Research and Development (5)  ·  Avid Radiopharmaceuticals (4)

Countries

United States (351)  ·  China (25)  ·  Canada (22)  ·  United Kingdom (15)  ·  Sweden (7)  ·  Belgium (6)  ·  Denmark (6)  ·  Egypt (6)  ·  Netherlands (6)  ·  Australia (5)  ·  Israel (5)  ·  France (4)  ·  Germany (4)  ·  Spain (4)  ·  Norway (3)

Top investigators

Li Luming, PhD (5)  ·  Danna Jennings, MD (4)  ·  Dawson Church, PhD (4)  ·  Josh D Woolley, MD/PhD (4)  ·  Colleen A Hanlon, PhD (3)  ·  Mehmet Sofuoglu, M.D.,Ph.D. (3)  ·  Michael Segal, MD PhD (3)  ·  Andrea Reinecke, PhD (2)  ·  Bradley C Lega, MD (2)  ·  Christopher P Cardozo, MD (2)  ·  Cristina Sampaio, MD, PhD (2)  ·  Dardo G Tomasi, Ph.D. (2)

Results publications

PMID 28642081, PMID 11143733, PMID 15474895, PMID 15931222, PMID 16677714, PMID 18174562, PMID 18426576, PMID 18984559, PMID 20097391, PMID 20501908, PMID 21176784, PMID 21569488, PMID 22246119, PMID 22459048, PMID 22581070, PMID 22654774, PMID 22905331, PMID 23134619, PMID 23438090, PMID 23481118, PMID 23763450, PMID 24006963, PMID 24761279, PMID 24938135, PMID 25182079, PMID 25276687, PMID 25447751, PMID 25581657, PMID 25885697, PMID 25948052, PMID 26111923, PMID 26158265, PMID 26203461, PMID 26364274, PMID 26619358, PMID 27137199, PMID 27206648, PMID 27520015, PMID 27575343, PMID 27763627, PMID 27814297, PMID 27869829, PMID 27909164, PMID 27918562, PMID 28521048, PMID 28551715, PMID 28709450, PMID 28789647, PMID 28849779, PMID 29282327

NIH funding

K01DA039299 (2), K12DA031794 (2), R01AA025247 (2), R01DA047368 (2), R35GM146822 (2), 1UG3HL161342-01A1 (1), 2018 (1), I01RX000825 (1), IK2RD000536 (1), K01DA043652 (1), K01DA046561 (1), K01DA056692 (1), K01MH109871 (1), K05AA014715 (1), K23AA030355 (1)